vet survey view tripl mirataz fecal
analyz insur sdma
messag conduct regular vet survey found confirmatori
interest zoeti tripl improv view abaxi market accept mab
vet continu like pet insur benefit next year
final kindr mirataz higher penetr expect yet
translat revenu pleas result nonetheless sdma
continu experi growth result mix elanco
favorit survey
zoeti top pick survey three posit develop came survey
zoeti data tripl confirm bullish view check cytopoint
suggest pain mab see accept preliminari check suggest vet
percept abaxi qualiti improv current expect slow share
loss us think possibl abaxi could return us market growth
second best pick survey robustli grow pet
health insur market believ acceler check suggest
vet survey recommend insur almost everi new patient vet offer
trupanion exam day offer lastli survey like underestim market given
corpor practic estim doubl revenu independ practic
embrac insur higher rate
kindr found posit data cytopoint suggest strong potenti
kindr in-develop compound furthermor found vet use
mirataz well ahead estim note increas drug util harder
make vet awar penetr clinic first step
found sdma continu see increas traction suggest
remain driver futur growth said believ market alreadi expect
perform well
found ok market urine/fec analyz biggest hindranc
note vet equip cost solv reset program
posit develop off-set lower expect net qualiti score
elanco think strong simparica trio off-set much benefit credelio
survey found lower credelio penetr though think much
sampl size note survey went prior bayer bayri acquisit
page analyst certif import disclosur
vet survey pharma diagnost insur
page analyst certif import disclosur
tripl chang entir landscap view pain medic interest well
think veterinarian might adopt simparica trio tripl first year rate
overal script like lag effect compar vet adopt rate trio market share would like
excess origin simparica market share estim
although vet hesit switch medic pet parent compliant believ simparica trio
might rare except
note tripl like high rate cannib first year howev
got low rate credelio adopt believ market share grow though like cap
trio launch perhap
deep cytopoint penetr confirm view vet administ monoclon antibodi clinic
posit read kindr compound zoeti pain product expect
buy zoeti kindr
page analyst certif import disclosur
tripl penetr might look like
remind tripl combin flea tick heartworm medic taken one cycl
sort misnom believ tripl would includ intestin worm addit heart worm
given competitor seed market fairli confid zoeti first market
tripl assum approv
although compani market drug prior approv compani typic begin leg work prior
chang market current competit product
chang structur size salesforc
educating/hir kol academ might lectur design independ studi around
page analyst certif import disclosur
tripl penetr might look like
survey found vet consid comfort price two import characterist flea
simparica trio like cannib revenu origin simparica
origin simparica price market share gain
believ zoeti intent underpr simparica market share gain order eas vet
switch simparica trio
vet get comfort trio time view
zoeti brand like help penetr vet current recommend bravecto/nexgard
page analyst certif import disclosur
market current look like
believ survey slightli underestim simparica credelio penetr believ
penetr rate respect
two vet said mistakenli said frontlin topic treatment anoth said sentinel
stop tick
page analyst certif import disclosur
price matter comfort
vet rank price clinic import characterist follow familiar age
administr schedul price pet parent final speed kill time
page analyst certif import disclosur
price matter comfort
although all-in price practic comfort compound score highli dont think mean
tripl wont succeed
think zoeti meaning flexibl price strategi
believ zoeti price premium sum price heartworm product flea tick
product standalon doesnt
like novel enough warrant premium zoeti under-penetrated could price
even discount benefit market share
sens zoeti price premium strateg purpos
room discount futur
set tone premium product
posit versu futur competitor
subtl differ name simparica simparica trio minim concern
lack familiar
page analyst certif import disclosur
flea tick heartworm highli develop product categori
trend topic oral flea tick heartworm medic happen sinc launch nexgard
expect trend continu net net oral move effect higher complianc rate less messi
us better chanc bought veterinarian survey found oral medic
recommend time think survey low
occasion find vet recommend topic one reason weve found prefer topic
vet seen advers reaction dog oral medic
page analyst certif import disclosur
equal prefer alreadi prescrib dog yet
percent patient would recommend tripl
surpris vet didnt seem signific differ opinion dog
alreadi flea tick prevent vs still believ tripl better
new patient alreadi simparica potenti evid could see immedi
page analyst certif import disclosur
percent patient would recommend tripl
excit patient survey veterinarian said would recommend
simparica trio caution question format lead
think
repres dog medic
probabl would repres annual revenu share competitor
found lack differ alreadi flea tick medic vs dog alreadi
prevent surpris
prior check typic found significantli lower willing chang medic
switch medic lead shop event clinic chewi com chwi
suggest us get vet switch bravecto nexgard/heartgard might imposs
page analyst certif import disclosur
less lead question lead first full year case view
previou check suggest vet heard trio ask question less lead way well
case specif name simparica trio
think conservat ask defin time-frame
believ there bia downward forc veterinarian speak practic previou
survey work suggest vet conserv speak vet
page analyst certif import disclosur
less lead question lead first full year case view
assum strongli agre half agre recommend simparica trio wed look
penetr rate alreadi excess origin simparica estim
use survey rough guid could see penetr rate us follow
full year penetr rate oral market high rate simparica cannib
word think simparica trio hit blockbust statu first year bulk
sale switch simparica origin simparica trio repres
longer term believ simparica trio could
base us revenu nexgard base
slightli optimist case world-wide total nexgard
estim still frame simparica trio market use nexgard bravecto popular medic
handl flea tick compon believ heartworm worm medic would upsid
bull case penetr flea tick heartworm
note simparica trio like well europ given low incid
page analyst certif import disclosur
ultra bullish monoclon antibodi
look cytopoint companion anim mab market baromet success
futur companion anim monoclon antibodi
background generalist veterinarian give inject medic vaccin clinic prior
cytpoint medic chronic care medic measur week
dose think cytopoint chang entir market small anim veterinarian might
vet survey tri cytpoint practic
page analyst certif import disclosur
monoclon antibodi pipelin
ultra bullish monoclon antibodi
anticip mab product near term blockbust potenti
expect kindr launch compound direct competitor cytopoint end
expect zoeti launch pain product cat end
potenti mab product less clear market timelin
expect oncolog mab pursu elanco zoeti kindr next five year
believ kindr launch epo-cat
page analyst certif import disclosur
half vet prescrib mirataz
vet survey tri mirataz
number state kindr last call
number well ahead expect use differ order
one vet comment still crush human mirtazapin
one vet comment use elanco entyc label
point quarterli revenu last quarter think penetr number clinic less import
increas util
soft check confirm
one vet comment mirataz im still wait use
net net view unchang regard mirataz peak sale
page analyst certif import disclosur
biggest growth area companion anim health
recommend insur still quit polar among veterinarian
prior research suggest vet either realli dislik insur adopt fulli
although survey found parent newli adopt dog cat recommend pet
insur see vet aggreg result come extrem
survey found higher rate recommend insur larger corpor hospit
page analyst certif import disclosur
biggest growth area companion anim health
opportun pet insur grow highlight low penetr rate pet insur
market research compani ibi estim insur penetr us less
although number higher due differ view constitut potenti insur dog/cat agre
wide under-penetrated
believ number one fact drive penetr insur accept veterinarian
check continu find increas interest vet medic insur pet
survey found newli adopt pet visit veterinarian receiv recommend get
insur appear prior check found roughli vet recommend
call confirm
page analyst certif import disclosur
trupanion express exam day offer thought
believ express key differenti
last sharehold letter trupanion express penetr less vet practic
survey found trupanion express penetr rate corpor vs non-
corpor hospit aggreg adopt rate right around adopt matrix
exam day offer second major differenti
trupanion express found corpor much like offer case vs
non-corpor aggreg percentag
page analyst certif import disclosur
new product domin new strategi domin zoeti
year drawn investor interest new product sale strategi right other
make pronounc chang watch
believ potenti disrupt announc product come fecal/urin analyz
biggest potenti chang reput come zoeti abaxi reput rub zoeti visa-
believ like new product launch hasnt announc anyth
come survey posit zoeti unchang
initi feedback urine/fec analyz demonstr market product didnt
overwhelm us enough believ there enough upsid justifi valuat
note survey work necessari understand fecal/urin analyz demand
call confirm
gener compani well diagnost market good
buy idexx
page analyst certif import disclosur
everyon win diagnost
remind investor long-term growth estim diagnost companion anim
market growth rate
market driven diagnost increas percent practic revenu
chang demographic/leg system young vet taught use diagnost rather reli
new innov push better standard care
diagnost outsourc chewi com
page analyst certif import disclosur
prevent medicin drive upward trend
believ share diagnost outsid insid lab move mode share
gain import stage grow market import
strategi center help hospit grow diagnost util
diagnost compani benefit
new frontier focu prevent medicin
impress find vet survey said rapidli increas prevent servic
vet disagre strongli disagre net net see paradigm shift prevent medicin addit
industri test lead test lead treatment
page analyst certif import disclosur
fecal/urin analyz
remind plan launch combin urine/fec analyz next year although dont yet know
exact spec instrument know market larg base number sampl run
although tradit product develop compani compani recent target
new product someth pleas
alreadi know market in-clin urin analysi look like abaxis/zoeti
urin sediment analyz market urin chemistri small market estim market
in-clin uranalysi almost grow doubl digit
companion anim parasit council capc estim fecal test run per year
although estim volum run insid clinic weve run
signific check find half volum sent survey consist
think total address market analyz would
test multiplie price
market potenti depend multipl factor insuffici accuraci non-start
inside/outsid lab prefer also figur end market
page analyst certif import disclosur
market fecal/urin look like
survey found roughli fecal sampl process clinic use fecal flotat method
interestingli ask percent volum would clinic fecal in-clin analyz
also got
two takeaway result
first think question bit complic survey user error
second think result least show product like appeal test clinic
total three vet current use refer lab fecal test said would switch
page analyst certif import disclosur
biggest problem adopt fecal/urin analyz wouldnt actual problem
vet highest figur said cost equip would biggest barrier adopt
bode well consid product like sold part reset program -- money program
exchang long-term consum contract
second pick note accuraci vs incumb method tough sinc predomin method
veterinarian microscop high rate human error particularli pm friday said believ autom
diagnost instrument held standard like driverless car word accuraci well excess human
page analyst certif import disclosur
fecal analyz survey ok context import
earli survey work analyz mix slightli posit ultim think well need survey work
unansw question
note lot veterinarian dont like handl fece dont know yet barrier opportun
addit instrument might limit handl
instrument appear better recept vet work insid clinic effect
continu push antech move volum refer lab
accept accuraci dont believ need go fda veterinarian
individu veterinarian respons avail request
page analyst certif import disclosur
sdma still idexx best trick
conceptu speak mani investor dont realiz sdma actual launch consid still play role
growth although prior check alway seen marker use increas want see fall
adopt curv
veterinarian sdma test still increas volum suspect lot disagre vca clinic
find number survey
think confirm idexx view innov bring multipl year growth market rate
page analyst certif import disclosur
prior survey expect abaxi potenti neg impact reput zoeti
abaxi alway good product abaxi tradit thrifti come packag market
salesforc view top concern abaxi acquisit potenti reput hit
vet werent remov diagnost answer abaxis/zoeti increas qualiti believ
zoeti abil improv market effort behind abaxi product fact abaxi qualiti improv
compar
rel expect abaxis/zoeti perform well net chang qualiti score line
well expect even account market share pleas contact us calcul net
chang qualiti score also includ neg opinion
page analyst certif import disclosur
zoeti updat revenu
estim
respect updat adjust ep
estim
respect
expect perfect newli energ abaxi
expect product launch expir
patent chang test protocol advers econom
competit manufactur risk currenc risk difficulti
valuat financi
rais pt round
prior pt base confid
sdma growth driver price target deriv
multipl ep estim
valuat steep idexx widen competit
gap suggest us potenti multi-year double-
digit earn growth although upsid
pt current level maintain buy rate given
long-term tailwind stock see meaning
growth ahead driven market share gain refer lab
increas util growth outsid us
zoeti rais pt due confid tripl
margin growth assum current trade multipl
hold appli adj ep estim
arriv pt
believ multipl valuat warrant
given confid abil util tripl
monoclon antibodi pain contribut
growth compani beyond
potenti upsid price target current level
maintain buy rate base confid
abil util tripl monoclon
antibodi pain contribut growth compani
beyond
page analyst certif import disclosur
non-gaap sale
non-gaap provis tax
net incom alloc non-controlling interest
less net loss /incom attribut non-controlling interest
page analyst certif import disclosur
